Eclipsys Technologies has confirmed that its strategy to
fix a flaw in the workflow engine for its SunriseXA clinical
information system is working. The move has helped Eclipsys boost
its share price by 27%.
In October, Eclipsys said that the SunriseXA workflow engine had
been linked to slow response times in processing orders and other
complex tasks, and at the time announced that it would begin the
process of installing an older engine. That announcement shaved off
39% of the company's value in a single day.
Alhough analysts hailed the admission as a step in the right
direction, they warned that it did little more than reiterate
Eclipsys' approach to fixing the response time issue.
"The company has achieved the first step in putting its XA
workflow problems behind them," said David Francis, an analyst at
Jefferies and Company, which has a "hold" recommendation on
Eclipsys and says that it still has work to do.
Eclipsys said that it had tested the software, using its older
Clinical Manager workflow engine with its SunriseXA database, and
found a greater than 30% performance gain over systems using the
entire Clinical Manager project which, Eclipsys said, validated its
approach to the problem.
The company also updated its timetable for future releases of
the software, noting that a version 3.3 of SunriseXA was upcoming,
with a more extensive release - version 3.5 - coming next
summer.
Brian Reid writes for IDG News
Service